Satsuma Pharmaceuticals Inc (STSA)


Stock Price Forecast

June 8, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Satsuma Pharmaceuticals Inc chart...

About the Company

satsuma pharmaceuticals is focused on developing best-in-class products to address the unmet needs of migraine sufferers.

CEO

John Kollins

Exchange

NASDAQ

Website

satsumarx.com

$17M

Total Revenue

25

Employees

$36M

Market Capitalization

-1.86

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $STSA News

No New Safety Signals Seen With Migraine Prevention Drug

9d ago, source: MedPage Today on MSN

DENVER -- No new safety signals emerged with daily atogepant (Qulipta) for migraine prevention, an interim analysis of a long ...

Takeda, Astellas, Sumitomo Mitsui Banking To Form JV For Incubation Of Early Drug Discovery Programs

4d ago, source:

The new JV will be for the incubation of early drug discovery programs, primarily originating from Japan and toward the creation of innovative therapeutics. The JV is expected to be established in mid ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...